Ameritas Advisory Services’s Rapport Therapeutics RAPP Stock Holding History

Ameritas Advisory Services’s Portfolio RAPP Stock Details RAPP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$208	Buy	+5	New	+$184	﹤0.01%	1891

Other funds holding RAPP

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TGV

TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Ameritas Advisory Services's RAPP Position: Q2 2026 in Review

Ameritas Advisory Services opened a new position in Rapport Therapeutics (RAPP) in Q2 2026: 5 shares worth $208. The stake represents ﹤0.01% of the portfolio and ranks #1891 among its holdings.

161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

Ameritas Advisory Services held 5 shares of Rapport Therapeutics worth $208 as of Q2 2026.
Rapport Therapeutics was a new Ameritas Advisory Services position in Q2 2026.
Rapport Therapeutics made up ﹤0.01% of Ameritas Advisory Services's portfolio in Q2 2026, its #1891 holding.
161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Ameritas Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.